A Phase 1b/2 randomized, open-label trial to evaluate the safety, tolerability, PK, and preliminary antitumor activity of immunotherapy-based treatment combinations in participants with metastatic pancreatic ductal adenocarcinoma. Participants will be assigned to one of several treatment arms, including etrumadenant + nab-paclitaxel + gemcitabine + atezolizumab.
Key Eligibility Criteria
- Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma
- No prior systemic treatment for pancreatic ductal adenocarcinoma